What is the difference between Argireline and BPC-157?

Argireline: Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects BPC-157: BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites.

Is Argireline FDA approved?

Argireline is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is BPC-157 FDA approved?

BPC-157 is the subject of a favorable FDA advisory committee vote but not FDA approved, and its legal status for compounding is unchanged. It is discussed for research and educational purposes only, not as medical guidance.

How is Argireline administered in research settings?

In research settings, Argireline is typically administered via the topical route. PeptideBase does not provide dosing or administration instructions.

How is BPC-157 administered in research settings?

In research settings, BPC-157 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Argireline vs BPC-157

Peptide Comparison

Argireline vs BPC-157

Name: Argireline vs BPC-157 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Argireline

Acetyl Hexapeptide-3

Skin & JointNot EvaluatedResearch Only

Half-life: N/A (topical)

18 providers listed

Full Argireline profile →

BPC-157

Body Protection Compound 157

RecoveryAdvisory Vote: FavorableResearch Only

Half-life: Under 30 minutes (plasma); no human PK data

703 providers listed

Full BPC-157 profile →

Bottom line

Argireline and BPC-157 target different goals — Argireline for SNARE complex (SNAP-25) competitive inhibition reducing expression line depth, BPC-157 for tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptide. They're compared here for reference, not as direct substitutes.

Quick Verdict

Argireline

Half-life

N/A (topical)

BPC-157

Half-life

Under 30 minutes (plasma); no human PK data

Different Goals

Argireline and BPC-157 target different goals — Argireline for Skin & Cosmetic, BPC-157 for Tissue Repair. They're compared here for reference; there isn't a single “better” choice between them.

Side-by-Side Comparison

Argireline

BPC-157

Mechanism Family

Skin & Cosmetic

Tissue Repair

Half-life

N/A (topical)

Under 30 minutes (plasma); no human PK data

FDA Status

not evaluated

advisory committee recommended

Admin Routes

topical

subcutaneous, oral

Availability

Research Only

Providers

18 listed

703 listed

FDA Update

—

Jul 2026

Avail. Notes

Cosmetic peptide (acetyl hexapeptide-3). Sold as cosmetic ingredient by Lipotec/Sederma. Not regulated as a drug by FDA. No NDA or IND. Cosmetic anti-wrinkle ingredient only.

Not FDA-approved for any human use; sold as a research chemical; WADA prohibited (S0). Placed on the interim FDA 503A "Category 2" list (significant safety risks) in September 2023. In February 2026 HHS announced an intention to move several peptides toward "Category 1," but the FDA did not reclassify BPC-157. In April 2026 the FDA removed BPC-157 from the Category 2 list because the nomination was withdrawn — this does not authorize compounding, and BPC-157 is not on the 503A bulks list. Provider pricing varies by concentration, formulation, and source; use the PeptideBase directory to compare active providers and current availability.

Research Evidence

Argireline

RCT · 3 key studies · most recent 2026

BPC-157

Cohort study · 14 key studies · most recent 2026

Research Citations

Argireline

RCT2017 · Journal of Cosmetic Dermatology

The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3: a prospective, ra…

RCT2013 · American Journal of Clinical Dermatology

The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-…

In vitro2026 · Biomater Adv

DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging.

BPC-157

Cohort2021 · Altern Ther Health Med

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

Animal2026 · Pharmaceuticals (Basel)

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…

Animal2026 · Sci Rep

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.

In vitro2026 · Int J Mol Sci

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.

+10 more

About Argireline

Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects

Research Areas

SNARE complex (SNAP-25) competitive inhibition reducing expression line depthwrinkle reduction documented in controlled human trialstopical cosmetic application — not a systemic peptidesoftening of dynamic lines over 4–8 weeks at 5–10% concentration

About BPC-157

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

Research Areas

tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptideanti-inflammatory via COX-2 and NF-κB pathway modulationangiogenesis and wound healing via VEGF and nitric oxide system upregulationoral or subcutaneous administration studied — systemic and local tissue effects documented

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Argireline

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

BPC-157

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Regulatory Notes

global — WADA

BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.

source

Used Together?

BPC-157

GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.

Price (per mg)

Argireline

Not enough vendor pricing yet.

BPC-157

$5.25/mg

$4.25 – $6.99 range

72 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Argireline

18 listed

Browse directory →

Providers offering

BPC-157

703 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

Related Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated October 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Argireline vs BPC-157 — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/argireline/bpc-157

https://peptidebase.io/peptides/compare/argireline/bpc-157 Methodology License Download JSON Download CSV